A clinical trial protocol to treat massive Africanized honeybee () attack with a new apilic antivenom by unknown
RESEARCH Open Access
A clinical trial protocol to treat massive
Africanized honeybee (Apis mellifera) attack
with a new apilic antivenom
Alexandre Naime Barbosa1, Leslie Boyer2, Jean-Philippe Chippaux3,4, Natalia Bronzatto Medolago5,
Carlos Antonio Caramori6, Ariane Gomes Paixão1, João Paulo Vasconcelos Poli1, Mônica Bannwart Mendes1,
Lucilene Delazari dos Santos7, Rui Seabra Ferreira Jr1,7 and Benedito Barraviera1,7*
Abstract
Background: Envenomation caused by multiple stings from Africanized honeybees Apis mellifera constitutes a
public health problem in the Americas. In 2015, the Brazilian Ministry of Health reported 13,597 accidents (incidence
of seven cases per 100,000 inhabitants) with 39 deaths (lethality of 0.25%). The toxins present in the venom, which
include melittin and phospholipase A2, cause lesions in diverse organs and systems that may be fatal. As there has
been no specific treatment to date, management has been symptomatic and supportive only.
Methods: In order to evaluate the safety and neutralizing capacity of a new apilic antivenom, as well as to confirm
its lowest effective dose, a clinical protocol was developed to be applied in a multicenter, non-randomized and
open phase I/II clinical trial. Twenty participants with more than five stings, aged more than 18 years, of both sexes,
who have not previously received the heterologous serum against bee stings, will be included for 24 months. The
proposed dose was based on the antivenom neutralizing capacity and the number of stings. Treatment will be
administered only in a hospital environment and the participants will be evaluated for a period up to 30 days after
discharge for clinical and laboratory follow-up.
Results: This protocol, approved by the Brazilian regulatory agencies for ethics (National Commission for Ethics on
Research – CONEP) and sanitation (National Health Surveillance Agency – ANVISA), is a guideline constituted by
specific, adjuvant, symptomatic and complementary treatments, in addition to basic orientations for conducting a
clinical trial involving heterologous sera.
Conclusions: This is the first clinical trial protocol designed specifically to evaluate the preliminary efficacy
and safety of a new antivenom against stings from the Africanized honeybee Apis mellifera. The results will
support future studies to confirm a new treatment for massive bee attack that has a large impact on public
health in the Americas.
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Background
African Apis mellifera scutellata bees were introduced
into the southeastern region of Brazil in 1956. Twenty-
six queens swarmed and initiated the Africanization of
the American continent. These new hybrids, known as
Africanized honeybees, are very defensive and attack en
masse, causing serious injuries in humans and other
animals. These bees have expanded their range and
today are found from Argentina to the United States of
America [1, 2]. Consequently, public health authorities
in Brazil included bee sting events as an object of
epidemiological vigilance as a consequence of the grow-
ing number of victims and of deaths related to this
envenomation.
A recent epidemiological study made it possible to
specify the factors concerning the incidence and severity
of bee stings in Brazil [3]. They represented 6% of cases
of envenomation and 9% of deaths due to animal en-
venomation, which denotes a high severity of bee stings.
The incidence predominated in southern Brazil. Stings
frequently occurred during recreational and professional
activities, both in suburban and rural settings, and this
explained why the incidence was fairly distributed for all
ages, although the masculine gender was more involved.
However, two thirds of the patients stung by bees arrived
at the hospital less than three hours after the bee stings,
which is very different from all other envenomated
patients who arrived significantly later. Asymptomatic
and mild envenomation accounted for up to 90% of
cases, moderate envenomation for 10–18% and severe
ones for 0.8–1.3%. The case fatality rate was 0.3 to 0.4%
in all regions. Nevertheless, the study does not specify
whether it was single or multiple punctures, i.e. it cannot
be determined whether death is related to anaphylactic
shock or envenomation after inoculation with a large
amount of bee venom.
In 2000, 1,440 cases, including three deaths, were
reported; in 2015 this number grew to 13,597 cases
with 39 deaths, that is, an increase of almost tenfold
in the number of cases in 15 years [3, 4]. Despite this
impressive increase in reported incidence and mortal-
ity, many regional specialists believe that these num-
bers remain underreported. Fig. 1 below demonstrates
this growth.
The physiopathology of this accident is complex due
to the interaction between the diverse toxic components
of the venom, the potential target organs and the im-
mune response of the victim [5, 6]. Generally, bee stings
can present two different outcomes:
 Anaphylaxis: occurs in individuals allergic to bee
venom. In these cases a single sting can cause
serious generalized allergic reactions, possibly
leading to death. These consequences are not related
to the toxicity of the venom due to the small
quantity inoculated. Treatment is limited to general
measures and the use of symptomatic drugs aiming
to control the anaphylaxis [7].
 Direct toxicity from the venom: occurs when there
are a substantial number of stings – generally more
than 200 in adults. In this case, the venom volume is
sufficient to cause damage to vital organs.
Prominent among the toxic components are melittin
and phospholipase A2, whose presence accounts for
more than 60% of the dry weight of the venom.
Direct injury to the cardiovascular, muscular,
neurological, dermatological, metabolic,
hematological, respiratory and renal systems can
lead to death [7, 8].
The clinical manifestations resulting from multiple
stings are: generalized pain, intense pruritus, flushing,
hyperthermia, papules, urticarial plaques, hypotension,
tachycardia, headache, nausea, vomiting, abdominal
colic, bronchospasms and psychomotor agitation, which
may subsequently evolve to a state of torpor, accompan-
ied by respiratory and cardiac failure and, principally,
severe renal failure [8–10]. The most common labora-
tory alterations are: leukocytosis with neutrophilia,
hemolysis, thrombocytopenia, disseminated intravascular
coagulation, rhabdomyolysis with increase of creatine
phosphokinase (CPK), elevation of the enzymes aspar-
tate aminotransferase (AST) and alanine amino transfer-
ase (ALT), increase of urea, creatinine and myoglobin in
the urine [8–10].
Mortality is elevated at the extremes of age [4]. In
children, due to lower body mass, envenomation can be
much more severe, since with many stings the concen-
tration of the toxic components is elevated. In the
elderly, greater risk involves such preexisting comorbidi-
ties as chronic renal, cardiac or respiratory failure. These
constitute an important additional risk factor in patients
who are victims of multiple stings.
Given that until the present there has been no spe-
cific treatment, a consortium of Brazilian researchers
developed the first antivenom for bee stings constituted
of heterologous antibodies against the toxins from the
venom and approved for clinical trial. In order to
bridge the gap between the laboratory workbench and
the patient, the objectives of this study were to
standardize a clinical protocol applicable to patients
affected by multiple stings from Africanized Apis melli-
fera honeybees, to evaluate safety and preliminary effi-
cacy, and to standardize the lowest dose of the new
antivenom. The absence of a previous standardized
clinical protocol justifies its publication in order to
open a discussion on the relevance of antivenom strat-
egy and methodology proposed.
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Methods
Antivenom development and dose proposal
Researchers from the Center for Studies of Venoms and
Venomous Animals (CEVAP) of the São Paulo State
University (UNESP) in partnership with the Vital Brazil
Institute (IVB), Brazil, developed the apilic antivenom. For
this, the principal toxins from the venom of Africanized
honeybee maintained at the Lageado Experimental
Farm, UNESP campus in Botucatu, São Paulo, Brazil,
were extracted and purified. Next, previously selected
horses were immunized with increasing doses of the
chosen antigens. These protocols are described in de-
tail in the developed guide for researchers and in the
patent submitted [7, 11].
The proposed dose of the new antivenom was calculated
taking into account the premises of the WHO Guideline
for the production control and regulation of snake anti-
venom immunoglobulins [12] that prioritize the quantity
of venom inoculated in the host, neutralization potency
and the proposed antivenom dose. For these calculations,
the authors relied on the fact that one bee inoculates dur-
ing one sting approximately 0.1 mg of venom [1]. Accord-
ing to the serum neutralization tests, each milliliter of
standardized antivenom neutralizes 1.25 mg of venom.
Therefore, 10 mL of antivenom should neutralize the
venom of 100 stings. The experimental validation of anti-
venom efficacy and preclinical tests are detailed in a paper
in progress.
Design of the Apis study
This is a multicenter, non-randomized and open phase I/
II clinical trial study to evaluate the safety, determine the
pharmacokinetic and proteomic profile, and confirm the
lowest antivenom dose, according to the severity of each
case. It will include 20 adult individuals, of both sexes,
afflicted with multiple stings from Africanized Apis melli-
fera honeybees. The study population will be of the type
non-probabilistic by convenience (or accidental) sample,
given the low demographic density of the studied
phenomenon and the extreme geographic decentralization
of this event. The sample size was estimated by consider-
ing examples of phase I/II clinical studies proposing to
study the safety and neutralizing power and to confirm
the minimum required dose of antivenom [12]. Not
performing the sample calculation is justified by the fact
that the efficacy outcome is not the target at this moment
given that there are no data on safety and adequate dose.
The study will last 36 months, with 24 months for
recruitment.
Objectives
 Primary objectives: to evaluate the safety of the
antivenom including number and severity of acute
adverse events, as well as deaths suspected to be
related to the intervention; and to confirm the
lowest effective dose when faced with different
quantities of venom inoculated in patients exposed
to multiple stings from Africanized honeybees.
 Secondary objectives: to correlate the severity of the
initial clinical condition with number of stings.
 Explanatory objectives: to evaluate the antivenom
neutralizing power by pharmacokinetic and
proteomic studies; and to evaluate the antivenom
pharmacokinetics and immunogenicity.
Outcomes
 Primary outcomes: to evaluate the antivenom safety
profile through laboratory and clinical adverse
events; to verify the proportion of individuals with
improvement in the initial clinical picture by
monitoring signs, symptoms and laboratory exams.
 Secondary outcomes: to evaluate the degree de
correlation between the number of stings and the
severity of the initial clinical picture (APACHE II).
Fig. 1 Temporal distribution of the number of cases reported for Africanized honeybee sting in Brazil between 2000 and 2015 [4]
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 Exploratory outcomes: to evaluate the
pharmacokinetic and immunogenic profile of
antivenom/venom at doses established by an analysis
of the blood samples collected at different moments
(before and at 2, 6, 12 and 24 h after heterologous
serum therapy); to evaluate the proteomic profile of
the antivenom as determined by the differential
expression of the proteins albumin, C-reactive
protein (CRP) and fibrinogen, by the presence
of the components melittin and phospholipase A2,
and by the heterologous serum protein profile of the
degradome and peptide/protein biomarkers.
Study participation agreement
Prior to the performance of any procedure related to the
study, the participants in the research and/or their fam-
ily members must be informed about its objectives, risks
and procedures. Those who consented to participate
must sign, date and initial the terms of free and in-
formed consent (TFIC). The process of obtaining the
TFIC must be documented on the patient’s chart. If the
consent and signature of the patient are impossible to
obtain, by virtue of his or her clinical condition, it is es-
sential to locate a family member or other responsible
party to provide them.
Approval from regulatory agencies
Approval from the Research Ethics Committee (CEP)
The National Commission for Ethics on Research (CONEP)
approved the clinical research protocol and the terms of
free and informed consent (TFIC). The investigators of the
other centers must send to the coordinating center a copy
of the approval by the local research ethics committee
(CEP) of the current version of the clinical study protocol,
the TFIC and its necessary revisions. The coordinating
CEP-CONEP system will oversee the conduct of the study.
Approval from the management of ANVISA Clinical Research
The National Health Surveillance Agency (ANVISA),
through intermediation of the General Management of
Drugs department, received all documentation of the
product, including the clinical research protocol, the guide
for researchers (a complete history of the development of
the product) and the other documents necessary for ana-
lysis and approval. This is the first time that an antivenom
against bee stings is evaluated in human’s clinical trial.
Registration in the ReBec
The Brazilian Clinical Trials Registry (ReBec) is a virtual
platform of free access to a registry of experimental and
non-experimental studies performed on humans and con-
ducted on Brazilian territory, by Brazilian and foreign re-
searchers. ReBec is a joint project of the Ministry of Health
(DECIT/MS), the Pan American Health Organization
(PAHO) and Oswaldo Cruz Foundation (FIOCRUZ). The
executive committee of ReBec is composed of the above-
mentioned institutions and ANVISA. The Apis study was
registered in ReBec http://www.ensaiosclinicos.gov.br/.
Centers participating in the study
All the Brazilian research centers registered in the
National Clinical Research Network (RNPC) will be
invited to participate.
Statistical analysis
The statistical analysis, as well as the choice of tests for
comparison among the research participants, will be exe-
cuted with respect to the presuppositions determined by
the results, characteristics and behavior of the variables in
the study. The binomial variables will be compared by
chi-square and Fisher’s exact test. The numerical variables
will be compared by the Student’s t test or U test of
Mann–Whitney [13, 14].
Results and Discussion
Regulatory agencies and participating centers
The clinical trial was registered in ReBec on August 21,
2014; approved by the Research Ethics Committee at the
Botucatu Medical School (CAAE: 19006813.4.1001.5411)
on October 21, 2013 (clinical protocol version 1), on
December 1, 2014 (clinical protocol version 2) and on June
6, 2016 (clinical protocol version 3). The study was autho-
rized by ANVISA on February 5, 2016 (Special Communi-
cation n. 11/2016, Process n. 25351.611582/2014-93, CE
Expedient: 1215967161).
Three research centers registered in the National Clin-
ical Research Network (RNPC) applied for and fulfilled
the regulatory prerequisites, namely:
 Clinical Research Unit (UPECLIN) of the Botucatu
Medical School, UNESP, this is the coordinating center.
 Clinical Research Center at Hospital Nossa Senhora
da Conceição, at the University of South Santa
Catarina (UNISUL) located in Tubarão, Santa
Catarina state.
 University Hospital at the Medical School of Federal
University of Triângulo Mineiro (UFTM) located in
Uberaba, Minas Gerais state.
Standardization of criteria for inclusion, exclusion and
discontinuation
Participants shall meet the following criteria.
Inclusion
 Having an age above 18 years for both sexes.
 Having diagnosis of an accident with bees of the
genus Apis.
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 Having agreement from the patient or a responsible
family member to receive the antivenom.
Exclusion
 Having had a previous adverse reaction to
heterologous serum produced in horses.
 Being pregnant.
 Having a chronic disease, including congenital or
acquired immunodeficiency.
Discontinuation
 Developing anaphylactic shock resistant to
the management protocol for reactions of
acute hypersensitivities.
 Withdrawing from the terms of free and
informed consent.
Plan of treatment (specific, adjuvant, symptomatic and
complementary)
Specific treatment
The WHO Guideline for the production control and
regulation of snake antivenom immunoglobulins [12]
suggests that the protocol prepared for the specific treat-
ment be based on the estimated quantity of venom inoc-
ulated by the bee and on the neutralizing capacity of the
antivenin. Thus, the authors suggested:
 Up to 5 stings: specific treatment is not indicated,
except for a medical criterion.
 Between 5 and 200 stings: two vials of apilic
antivenom.
 Between 201 and 600 stings: six vials of apilic
antivenom.
 Above 600 stings: ten vials of apilic antivenom.
After the dose is determined by the attending medical team,
the vials must be opened and their content aspirated by
means of a syringe. Next, insert all the content into a flask
containing 250 mL of normal 0.9% saline solution, previously
emptied. This flask containing the antivenom must be con-
nected into a Y formation with another flask containing
250 mL of 0.9% saline. One large-caliber vein of the forearm
must be catheterized and these two contents need to be
infused in the Y within two hours. All patients must be hospi-
talized and monitored throughout the infusion by the con-
tinuous presence of the hospital staff at the patient’s bedside.
The team must also have at their disposal the drugs and
equipment necessary for the treatment of mild or severe ad-
verse reactions. Any adverse events and signs and symptoms
of possible toxicity must be noted on the patient’s chart.
Adjuvant treatment
The adjuvant treatment aims to maintain the patient
and avoid hemodynamic shock, preserve kidney func-
tion, diminish cerebral edema and prevent the dysfunc-
tions resulting from hemoglobinuria. Thus, the following
is proposed:
 Replenish volume by hydrating patient vigorously
with 0.9% saline, after catheterization of a large-
caliber peripheral vein, in order to ensure
hemodynamic stability. Always maintain arterial
pressure levels above 90 × 60 mmHg.
 Use vasoactive drugs including dopamine and/or
noradrenaline to treat hypotension refractory to the
volume, at the discretion of the medical staff.
 Suspect rhabdomyolysis when the level of creatine
phosphokinase (CPK) is above 5,000 U/mL. The
presence of dark urine, of oliguria and/or anuria
may also denote the presence of rhabdomyolysis. In
this case the volume of 0.9% saline to be infused will
be 20 mL/kg, running freely, being repeatable up to
three times. The objective will be to maintain a
urinary volume between 2 and 3 mL/kg/hour.
Vigorous hydration must be maintained until CPK
reaches levels below 1,000 U/mL.
 In the presence of refractory anuria or oliguria,
require an evaluation from a nephrologist for
potential hemodialysis.
 In the presence of electrolytic disturbances such as
alterations in levels of Na+, K+, Ca++ or Mg++, these
parameters should be closely monitored.
Hyperkalemia and hypocalcemia, when present,
must be corrected according to the protocols of the
referring services.
Symptomatic treatment
At the discretion of the medical team, goals for the
patient include:
 To treat and prevent hypersensitivity reactions
inherent to venom or antivenom. For this, use:
➢ antihistamines – inject intramuscularly, one
vial of 50 mg of promethazine or similar option
upon the arrival of the patient; repeat every six
hours if necessary;
➢ corticosteroids – administer intravenously,
200 mg of hydrocortisone or similar option upon
the patient’s arrival; repeat every six hours if
necessary. This scheme could be maintained for 3
to 5 days, according to the clinical evolution;
➢ when anaphylactic shock is suspected – if the
patient presents severe hypotension and in the
absence of a palpable pulse, inject subcutaneously
500 μg (0.5 mL) of aqueous adrenaline 1:1,000.
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 Treat the pain: inject intramuscularly, one vial of
petidine chlorhydrate 50 mg or similar; repeat every
six hours if necessary.
 In the presence of bronchospasm: utilize a catheter
of oxygen (O2) associated with bronchodilators of
the type β-2-agonist inhalants (salbutamol, pheno-
terol or terbutaline), at customary doses used at the
referring center. Continue as needed until the
disappearance of symptoms.
Complementary treatment
 Catheterize a large-caliber peripheral vein. In critical
patients use central venous access.
 Apply cardiac monitor and O2 saturation meter.
 Removal of the stingers should be performed
immediately after stabilization of the clinical
parameters of the patient. The count will help
estimate the amount of antivenom to be administered.
Other observations
 Apply vesical and nasogastric probe when indicated.
 Apply potassium permanganate diluted 1:40.000, for
antisepsis of the skin affected by the stings.
 Apply enteral feeding containing about 2,000 cal per
day when indicated.
 Maintain fluids, electrolytes and acid–base status
as indicated.
 Perform tracheotomy and/or oral-tracheal intub-
ation with mechanical ventilation, when indicated.
 Perform peritoneal dialysis and/or hemodialysis,
when there is acute kidney failure.
 Prevent the formation of bedsores.
 Avoid secondary respiratory infections.
Conduct according to the number of stings and the
presence or absence of anaphylactic reaction
Up to five stings
 Without anaphylactic shock:
➢ remove all of the stingers correctly;
➢ prescribe hydrocortisone ointment in isolation
or associated with 5% menthol;
➢ prescribe dextrochlorpheniramine 6 mg orally,
every eight hours as needed;
➢ apilic antivenom is not indicated.
 In the presence of anaphylactic shock:
➢ catheterize access of a large-caliber or central
vein to hydrate the patient;
➢ follow the protocol contained in the
symptomatic treatment item;
➢ remove all the stingers correctly;
➢ apilic antivenom is not indicated.
Up to 200 stings
 Without anaphylactic shock:
➢ remove all the stingers correctly;
➢ catheterize a central vein for hydration of the
patient;
➢ follow the protocol contained in the
symptomatic treatment item;
➢ always hospitalize the patient;
➢ apply two vials of apilic antivenom.
 In the presence of anaphylactic shock:
➢ catheterize a central vein for hydration of
the patient;
➢ follow the protocol contained in the
symptomatic treatment item;
➢ remove all the stingers correctly;
➢ these individuals must always be hospitalized
and may require treatment in an intensive care
unit (ICU);
➢ apply two vials of apilic antivenom.
Up to 600 stings
 Without anaphylactic shock:
➢ catheterize a central vein for hydration of the
patient;
➢ follow the protocol contained in the
symptomatic treatment item;
➢ remove all the stingers correctly;
➢ these individuals must always be hospitalized in
an ICU;
➢ apply six vials of apilic antivenom.
 In the presence of anaphylactic shock:
➢ catheterize a central vein for hydration of the
patient;
➢ follow the protocol contained in the
symptomatic treatment item;
➢ remove all the stingers correctly;
➢ these individuals may need to be hospitalized in
an ICU;
➢ apply six vials of apilic antivenom.
More than 600 stings
 Without anaphylactic shock:
➢ catheterize a central vein for hydration of the
patient;
➢ follow the protocol contained in the
symptomatic treatment item;
➢ remove all the stingers correctly;
➢ these sick individuals in general require
hospitalization in an ICU;
➢ apply ten vials of apilic antivenom.
 In the presence of anaphylactic shock:
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➢ catheterize a central vein for hydration of the
patient;
➢ follow the protocol contained in the
symptomatic treatment item;
➢ remove all the stingers correctly;
➢ these sick individuals in general require
hospitalization in an ICU;
➢ apply ten vials of apilic antivenom.
Clinical parameters
Product safety will also be evaluated through the clinical
parameters verified in the evaluations, via both labora-
tory exams and adverse events that will have occurred
during the study.
Adverse event (AE)
According to the International Council for Harmonisa-
tion of Technical Requirements for Pharmaceuticals for
Human Use (ICH) [15], an adverse event is any undesir-
able clinical occurrence in a patient or participant in
clinical research that receives or utilizes a pharmaceut-
ical product and that does not necessarily present a
causal relation to this treatment. Thus, an adverse event
can be any unfavorable unintentional signal (including
an abnormal laboratory finding, symptom or disease
temporally associated with the use of a product under
investigation, considered related or not to it). Preexisting
conditions that worsen during a study must be reported
as an AE. The events observed during a clinical study
should be reported in the patient’s chart (source docu-
ment), on the page of events of the electronic clinical
registry and must be classified as to:
 Intensity
➢ minimal (degree I): discomfort perceived, but
without interruption of normal daily activity;
➢ moderate (degree II): discomfort sufficient to
reduce or inhibit daily activity;
➢ severe (degree III): incapacity to work or
perform normal daily activity;
➢ risk to life (degree IV): represents an immediate
risk to life;
➢ death (degree V).
 Causal relation
➢ probable: the temporal relation is well defined
without the existence of another possible causal
factor. In this case, there is an almost certain
relationship between the reaction and the
medicament;
➢ possible: a temporal relation between an event
and the administration of a medicament is well
defined, but there is another possible causal factor;
➢ remote: a relationship with the medicament is
improbable, but cannot be definitively discarded;
➢ not related: a temporal relationship between
an event and the ingestion or administration of a
medicament is nonexistent or doubtful, or there
exists another factor that may be identified as a
causal factor of the reaction.
Observation For the current study, an adverse event is
considered any unfavorable and unintended signal that
occurs after administration of the antivenom against bee
stings. Conditions prior to such administrations must be
registered as medical history.
Serious adverse event (SAE)
A serious adverse event is an AE that occurs during any
phase of the study and that meets the following criteria:
it threatens life; it results in death or a significant or per-
manent incapacity, congenital anomaly, hospitalization
or the prolongation of an existent condition.
Serious adverse events also should be classified ac-
cording to the guidelines of the previous item, filled out
in the SAE formulary, sent to the coordinating center
within 24 h of obtaining the knowledge by means of a
virtual study platform and should be reported concomi-
tantly with the system CEP-CONEP. The coordinating
center will immediately notify ANVISA and subse-
quently the Department of Science and Technology in
the Ministry of Health (DECIT/SCTIE/MS).
Pregnancy
The occurrence of pregnancy during the study will need
to be communicated immediately to the coordinating
center via a pregnancy report formulary and reported
concomitantly to the system CEP-CONEP. For such an
occurrence, the participant would need to discontinue
participation in the study.
Risks and benefits
Risks:
 Acute hypersensitivity to heterologous serum.
 Adverse events intrinsic to heterologous serum.
 Delayed hypersensitivity to heterologous serum.
Benefits:
 Neutralization of inoculated venom, with
interruption of its toxicity.
 Support to anaphylactic reactions related to
envenomation.
Subsidiary laboratory tests
To evaluate the safety parameters, tests will be required
on hospitalization days one, two, five and ten, and at
follow up (10, 20 and 30 days after hospital dis-
charge) (Table 1).
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Complementing the results of the laboratory exams, a
proteomic evaluation will also be performed by degradome
analysis, seeking to evidence eventual biomarkers respon-
sible for physiological and clinical alterations [16, 17]. Fur-
thermore, a pharmacokinetic profile of venom and of a new
antivenom will be performed utilizing immunoenzymatic
methods (ELISA) due to their sensitivity, reproducibility,
ease of execution and low cost. Thus, the trial denominated
“venenomia” will have the objective of determining
the kinetics of circulating toxins and antivenom, aid-
ing in the diagnosis, in the determination of accident
severity and in the evaluation of heterologous serum
therapy efficacy [18–20].
Management of documents and publication policy
According to the law, all data obtained should be treated
with discretion to ensure the privacy rights of the par-
ticipant. The coordinating center must review the source
Table 1 Laboratory tests requested during hospitalization and follow-up
Procedures HOSPITALIZATION FOLLOW-UP
Day 1 Day 2 Hospital discharge Return 1 (R1) (10 days
after discharge)
Return 2 (R2) (20 days
after discharge)
Return 3 (R3) (30 days
after discharge)
Application of FICT X
Demographic data X
Clinical history X
Clinical exam X X X X X X
Concomitant medications X X X X X X
Adverse events X X X X X X
Vital signs Xa X X X X X
Hemogram X X X X X X
Urine type I Xb X X X X X
Urea X X X X X X
Creatinine X X X X X X
AST X X X X X X
ALT X X X X X X
Alkaline phosphatase X X X X X X
Gama GT X X X X X X
Bilirubin (direct) X X X X X X
Bilirubin (indirect) X X X X X X
Fasting blood sugar X X X X X X
Cholesterol (total and fractions) X X X X X X
Fibrinogen Xb X X X X X
C-reactive protein Xb X X X X X
ESR Xb X X X X X
PT Xb X X X X X
APTT Xb X X X X X
CPK Xb X X X X X
Albumin X X X X X X
Globulin X X X X X X
Pharmacokinetic profile Xc X X X X X
Proteomic profile Xd X X X X X
Pregnancy test Xe
FICT free and informed consent term, AST aspartate aminotransferase, ALT alanine amino transferase, gama GT: gamma glutamyl transferase, CRP C-reactive
protein, ESR erythrocyte sedimentation rate, PT prothrombin time, APTT activated partial thromboplastin time, CPK creatine phosphokinase
aThe vital signs should be taken every 30 min during the infusion and every hour through the first 12 h after the infusion
bCollect before and 12 h after termination of the infusion
cEvaluate the profile and level of the antibodies IgG and IgM against the antivenom infusion (before and at 2, 6, 12 and 24 h after infusion)
dEvaluate the profile of the different heterologous serum proteins in the antivenom (before and at 2, 6, 12 and 24 h after infusion)
eIn special cases and at the investigator’s discretion this test could be repeated
Barbosa et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2017) 23:14 Page 8 of 10
document (case reports, charts and medical registries)
for confirmation and registration. The research ethics
committee (CEP) of each partner institution must ap-
prove the clinical research protocol, the the guide for re-
searchers, the terms of free and informed consent
(TFIC) and other information for the recruitment of
patients, in addition to accompanying the conduction of
the study. All the documentation (source documents,
e-CRFs, laboratory exams, registries of medication dis-
pensations in the study, correspondence related to the
CEP and other annotations), must be kept on file for
at least five years, in a location of restricted access.
The coordinating institution undertakes to publish and
disseminate the results obtained in an indexed peer-
reviewed journal with a high impact factor. The choice
of authors and collaborators will be based on the
number of patients included, on the quantity of selec-
tion failures and on adherence to the procedures pro-
posed. Moreover, if in the future any participating
investigator wishes to use data from this study in
publications or presentations, he or she will have to
communicate such intention to the coordinating cen-
ter 60 days prior to submission.
Conclusions
Envenomation from bee stings are of great epidemio-
logical importance in Brazil due to the high annual num-
bers of cases and deaths. This scenario may be even
worse because of incomplete reporting by the attending
health facilities. As the Africanized bee Apis mellifera is
not restricted to Brazilian territory, the number of
victims throughout the American continent is still
unknown. Despite the relevance of the envenomation a
double gap is perceived in the attention to victims of
multiple stings, namely: the lack of standardized proto-
col with measures in the care of basic and advanced
supports to life; and the lack of a specific antidote that
inactivates the toxic fractions of this venom.
This study intends to propose a protocol of measures
that include a triad of treatments standardized for the
stabilization and general support of the patient (adju-
vant, symptomatic and complementary), in addition to a
specific treatment with a new antivenom, whose safety
and preliminary efficacy will be evaluated. An important
measure of the complementary treatment, for example,
is the fast removal of the stingers after a massive attack,
which should be performed immediately after stabilization
of the clinical parameters of the patient [21, 22]. The
count will help to estimate the amount of antivenom to be
administered.
The nonperformance of conventional phase I clinical
trials in healthy individuals to evaluate novel antivenoms
produced in animals is justified by the risk of immediate
reactions (anaphylaxis) and late reactions (heterologous
serum disease) resulting from potential future exposures.
Given the existence in Brazil of 13 available heterologous
sera produced in horses, it cannot be ruled out that
eventually one participant in “voluntary” research for a
phase I conventional study may in the future require
treatment by one of these products. This is a general
agreement among researchers and official documents
that address the theme, especially the WHO Guideline
for the production control and regulation of snake
antivenin immunoglobulins [12, 23–25].
This initiative, previously unpublished in the global
literature, will have the potential to generate results that
corroborate subsequent phases of the study, with the
objective of making viable a specific treatment for this
important, but neglected risk to public health in the
American continent. Furthermore, the Apis study is
meant to bring together measures for the support and
general stabilization of patients who are victims of mul-
tiple bee stings, an endeavor of fundamental usefulness
for health professionals in Brazil and other countries
affected by this problem.
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